The earnings call reflected a company facing significant challenges, particularly in device sales and international markets, especially China. However, there were positive signs in consumable sales growth and cost reductions, indicating efforts to stabilize and improve operational efficiency.

Company Guidance

During the Beauty Health Company's Q3 2024 earnings call, management provided key guidance metrics highlighting a strategic focus on enhancing sales execution, operational excellence, and financial discipline. The company reported third-quarter revenue of $78.8 million, a 19.1% year-over-year decline, while achieving a 69.5% adjusted gross margin due to a favorable sales mix toward consumables, which grew by 10.4% to $51.2 million. Device sales faced pressure, reflecting a 45.9% decline, with total units sold at 1,118. The company noted a strategic shift to consolidate manufacturing operations in the U.S. by year-end and to implement a tiered pricing strategy to mitigate economic headwinds. Operating expenses decreased by 10.6% to $62.2 million, contributing to an adjusted EBITDA of $8.1 million. Looking ahead, Beauty Health projects full-year 2024 sales between $322 million to $332 million and adjusted EBITDA ranging from negative $2 million to positive $4 million, indicating continued challenges in the international markets, particularly China, and a focus on cost management to drive profitability in 2025.

Adjusted Gross Margin Improvement

Achieved an adjusted gross margin of 69.5% in Q3 2024, up from previous quarters, driven by lower inventory-related charges and a favorable mix shift towards consumable net sales.

Consumable Sales Growth

Consumable sales increased by 10.4% in Q3 2024, with strong performance in the Americas and EMEA regions, contributing to a total of $51.2 million.

Operational Cost Reduction

Operating expenses decreased by 10.6% to $62.2 million in Q3 2024, with $31.4 million in cost savings for the first nine months of the year compared to the prior year.

Strategic Manufacturing Consolidation

Decided to consolidate manufacturing operations into the U.S. facility, expected to increase quality and efficiency.

---

Beauty Health (SKIN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SKIN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 13, 2021	2021 (Q1)	-0.03 / -0.02	-0.158	87.34% (+0.14)	―	―
Aug 10, 2021	2021 (Q2)	<0.01 / 0.08	-0.181	145.86% (+0.26)	―	―
Nov 09, 2021	2021 (Q3)	-0.01 / 0.01	0	―	―	―
Feb 22, 2022	2021 (Q4)	>-0.01 / <0.01	-0.02	145.00% (+0.03)	―	―
May 10, 2022	2022 (Q1)	<0.01 / -0.05	-0.02	-140.00% (-0.03)	―	―
Aug 09, 2022	2022 (Q2)	>-0.01 / 0.01	0.083	-85.54% (-0.07)	―	―
Nov 08, 2022	2022 (Q3)	0.01 / 0.05	0.015	246.67% (+0.04)
Feb 28, 2023	2022 (Q4)	0.04 / 0.06	0.009	522.22% (+0.05)
May 10, 2023	2023 (Q1)	-0.03 / -0.04	-0.048	12.50% (<+0.01)
Aug 09, 2023	2023 (Q2)	0.05 / 0.06	0.012	408.33% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

SKIN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2024	$1.70	$1.85	+8.82%
Aug 08, 2024	$1.29	$1.12	-13.18%
May 09, 2024	$3.59	$2.74	-23.68%
Mar 12, 2024	$3.59	$4.25	+18.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---